Search

Your search keyword '"Fleischhauer, K."' showing total 639 results
Start Over Author "Fleischhauer, K."
639 results on '"Fleischhauer, K."'

1. Risk associations between HLA-DPB1 T-cell epitope matching and outcome of unrelated hematopoietic cell transplantation are independent of HLA-DPA1

Author

Baxter-Lowe, Lee Ann, Fleischhauer, K, Fernandez-Viña, MA, Wang, T, Haagenson, M, Battiwalla, M, Baxter-Lowe, LA, Ciceri, F, Dehn, J, Gajewski, J, and Hale, GA

Abstract

HLA-DP antigens are beta-alpha heterodimers encoded by polymorphic HLA-DPB1 and -DPA1 alleles, respectively, in strong linkage disequilibrium (LD) with each other. Non-permissive unrelated donor (UD)-recipient HLA-DPB1 mismatches across three different T-c

Published
2014

2. Common and well‐documented HLA alleles: 2012 update to the CWD catalogue

Author

Mack, SJ, Cano, P, Hollenbach, JA, He, J, Hurley, CK, Middleton, D, Moraes, ME, Pereira, SE, Kempenich, JH, Reed, EF, Setterholm, M, Smith, AG, Tilanus, MG, Torres, M, Varney, MD, Voorter, CEM, Fischer, GF, Fleischhauer, K, Goodridge, D, Klitz, W, Little, A‐M, Maiers, M, Marsh, SGE, Müller, CR, Noreen, H, Rozemuller, EH, Sanchez‐Mazas, A, Senitzer, D, Trachtenberg, E, and Fernandez‐Vina, Marcelo

Subjects
Biological Sciences, Biomedical and Clinical Sciences, Genetics, Alleles, Databases, Genetic, Gene Frequency, Genetic Loci, Genetics, Population, HLA Antigens, Histocompatibility, Histocompatibility Testing, Humans, Terminology as Topic, allele prevalence, common allele, common and well-documented, human leukocyte antigen, sequence-based typing, well-documented allele, Clinical Sciences, Immunology
Abstract

We have updated the catalogue of common and well-documented (CWD) human leukocyte antigen (HLA) alleles to reflect current understanding of the prevalence of specific allele sequences. The original CWD catalogue designated 721 alleles at the HLA-A, -B, -C, -DRB1, -DRB3/4/5, -DQA1, -DQB1, and -DPB1 loci in IMGT (IMmunoGeneTics)/HLA Database release 2.15.0 as being CWD. The updated CWD catalogue designates 1122 alleles at the HLA-A, -B, -C, -DRB1, -DRB3/4/5, -DQA1, -DQB1, -DPA1 and -DPB1 loci as being CWD, and represents 14.3% of the HLA alleles in IMGT/HLA Database release 3.9.0. In particular, we identified 415 of these alleles as being 'common' (having known frequencies) and 707 as being 'well-documented' on the basis of ~140,000 sequence-based typing observations and available HLA haplotype data. Using these allele prevalence data, we have also assigned CWD status to specific G and P designations. We identified 147/151 G groups and 290/415 P groups as being CWD. The CWD catalogue will be updated on a regular basis moving forward, and will incorporate changes to the IMGT/HLA Database as well as empirical data from the histocompatibility and immunogenetics community. This version 2.0.0 of the CWD catalogue is available online at cwd.immunogenomics.org, and will be integrated into the Allele Frequencies Net Database, the IMGT/HLA Database and National Marrow Donor Program's bioinformatics web pages.

Published
2013

9. Incidence, risk factors and clinical outcome of leukemia relapses with loss of the mismatched HLA after partially incompatible hematopoietic stem cell transplantation

Author

Crucitti, L, Crocchiolo, R, Toffalori, C, Mazzi, B, Greco, R, Signori, A, Sizzano, F, Chiesa, L, Zino, E, Lupo Stanghellini, M T, Assanelli, A, Carrabba, M G, Marktel, S, Marcatti, M, Bordignon, C, Corti, C, Bernardi, M, Peccatori, J, Bonini, C, Fleischhauer, K, Ciceri, F, and Vago, L

Published
2015
Full Text
View/download PDF

10. Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors

Author

Peccatori, J, Forcina, A, Clerici, D, Crocchiolo, R, Vago, L, Stanghellini, M T L, Noviello, M, Messina, C, Crotta, A, Assanelli, A, Marktel, S, Olek, S, Mastaglio, S, Giglio, F, Crucitti, L, Lorusso, A, Guggiari, E, Lunghi, F, Carrabba, M, Tassara, M, Battaglia, M, Ferraro, A, Carbone, M R, Oliveira, G, Roncarolo, M G, Rossini, S, Bernardi, M, Corti, C, Marcatti, M, Patriarca, F, Zecca, M, Locatelli, F, Bordignon, C, Fleischhauer, K, Bondanza, A, Bonini, C, and Ciceri, F

Published
2015
Full Text
View/download PDF

12. Risk associations between HLA-DPB1 T-cell epitope matching and outcome of unrelated hematopoietic cell transplantation are independent of HLA-DPA1

Author

Fleischhauer, K, Fernandez-Viña, M A, Wang, T, Haagenson, M, Battiwalla, M, Baxter-Lowe, L A, Ciceri, F, Dehn, J, Gajewski, J, Hale, G A, Heemskerk, M B A, Marino, S R, McCarthy, P L, Miklos, D, Oudshoorn, M, Pollack, M S, Reddy, V, Senitzer, D, Shaw, B E, Waller, E K, Lee, S J, and Spellman, S R

Published
2014
Full Text
View/download PDF

14. Comparative evaluation of biological HLA-DPB1 mismatch models for survival and graft versus host disease prediction after unrelated donor hematopoietic cell transplantation

Author

Lorentino, F, Sacchi, N, Oldani, E, Miotti, V, Picardi, A, Gallina, Am, Crivello, P, Bernasconi, P, Saccardi, R, Farina, L, Benedetti, F, Cerno, M, Grassi, A, Bruno, B, Patriarca, F, Ciceri, F, Fleischhauer, K, Vago, L, Bonifazi, F, Lorentino, F., Sacchi, N., Oldani, E., Miotti, V., Picardi, A., Gallina, A. M., Crivello, P., Bernasconi, P., Saccardi, R., Farina, L., Benedetti, F., Cerno, M., Grassi, A., Bruno, B., Patriarca, F., Ciceri, F., Fleischhauer, K., Vago, L., and Bonifazi, F.

Subjects
HLA, Graft-versus-Host-Disease, unrelated donor selection, Medizin, Settore MED/15, Stem Cell Transplantation
Abstract

CA Fleischhauer

Published
2020

15. Impact of HLA-G polymorphism on the outcome of allogeneic hematopoietic stem cell transplantation for metastatic renal cell carcinoma

Author

Olle Ringdén, Roberto Crocchiolo, Fleischhauer K, Marco Bregni, Omasic B, Silvia Gregori, Benedetta Mazzi, Didier Blaise, Jacopo Peccatori, L Barkholt, J.-O. Bay, Christophe Picard, Fabio Ciceri, Giada Amodio, Trinca S, Role of intra-Clonal Heterogeneity and Leukemic environment in ThErapy Resistance of chronic leukemias (CHELTER), Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Crocchiolo, R., Ringden, O., Bay, J. -O., Blaise, D., Omasic, B., Mazzi, B., Picard, C., Trinca, S., Barkholt, L., Peccatori, J., Gregori, S., Amodio, G., Fleischhauer, K., Ciceri, F., and Bregni, M.

Subjects
Adult, Male, 0301 basic medicine, Oncology, medicine.medical_specialty, [SDV]Life Sciences [q-bio], medicine.medical_treatment, Medizin, Hematopoietic stem cell transplantation, Human leukocyte antigen, Malignancy, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Renal cell carcinoma, HLA-G, Internal medicine, medicine, Carcinoma, Humans, Neoplasm Metastasis, Carcinoma, Renal Cell, Survival rate, Aged, HLA-G Antigens, Transplantation, Polymorphism, Genetic, business.industry, Hazard ratio, Hematopoietic Stem Cell Transplantation, [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology, Hematology, Middle Aged, medicine.disease, 3. Good health, Survival Rate, Treatment Outcome, 030104 developmental biology, Female, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, 030215 immunology
Abstract

International audience; Renal cell carcinoma (RCC) is particularly sensitive to immune intervention. HLA-G, a non-classical HLA class I molecule with immunomodulatory properties, has been studied with regard to outcome after hematopoietic stem cell transplantation (HSCT), in particular the 14 bp insertion/deletion polymorphism in the 3' untranslated region. Here we analyzed n=56 patients affected by metastatic RCC who received an allogeneic HSCT between 1998 and 2006 in Milano, Marseille, Clermont-Ferrand and Stockholm. The 14 bp polymorphism was analyzed in correlation with overall survival (OS), PFS, acute and chronic GvHD. With a median follow-up of 13 years, a trend towards better outcome was observed when homozygosity for the 14bp-del allele was present: multivariate hazard ratio was 0.50 (95% confidence interval (CI): 0.23-1.13; P=0.10) and 0.57 (95% CI: 0.26-1.26; P=0.17) for OS and PFS, respectively, when 14bp-del/del was compared with 14bp-ins/X. Further exploratory analysis revealed a significant association between T/C at p3003 and improved OS (P=0.05) and PFS (P=0.006) compared with T/T. To our knowledge this is the first study on HLA-G and outcome after HSCT for a solid malignancy. After a coordinated multicenter study, we found that the more tolerogenic polymorphisms (14bp-del/del) is associated with better PFS and OS. The finding on p3003 deserves further investigation.Bone Marrow Transplantation advance online publication, 13 November 2017; doi:10.1038/bmt.2017.243.

Published
2017

16. Beneficial role of CD8+T-cell reconstitution after HLA-haploidentical stem cell transplantation for high-risk acute leukaemias

Author

Bondanza, A., Ruggeri, L., Noviello, M., Eikema, D.J., Bonini, C., Chabannon, C., Werf, S. van der, Biezen, A. van, Wreede, L.C. de, Crucitti, L., Vago, L., Merluzzi, M., Massei, M.S., Veelken, H., Koc, Y., Bader, P., Gruhn, B., Locatelli, F., Ciceri, F., Toubert, A., Velardi, A., Bernardo, M.E., Dazzi, F., Ellard, R., Fleischhauer, K., Greco, R., Hudecek, M., Kohl, U., Kuball, J., Malard, F., Pedrazzoli, P., Rocha, V., Ruggeri, A., Urbano-Ispizua, A., Wang, J.F., Wieten, L., EBMT Cell Therapy Immunobiol Worki, Bondanza, Attilio, Ruggeri, Loredana, Noviello, Maddalena, Eikema, Dirk-Jan, Bonini, Chiara, Chabannon, Christian, van der Werf, Steffie, van Biezen, Anja, de Wreede, Liesbeth C., Crucitti, Lara, Vago, Luca, Merluzzi, Mara, Massei, Maria Speranza, Veelken, Hendrik, Koc, Yener, Bader, Peter, Gruhn, Bernd, Locatelli, Franco, Ciceri, Fabio, Toubert, Antoine, Velardi, Andrea, MUMC+: DA TI Laboratorium (9), RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, and MUMC+: DA TI Staf (9)

Subjects
Male, Oncology, BLOOD, COUNT, Medizin, CHILDREN, CD8-Positive T-Lymphocytes, DISEASE, 0302 clinical medicine, Risk Factors, hemic and lymphatic diseases, Cytotoxic T cell, Registries, Child, INDEX, Leukemia, Hematology, Middle Aged, RECOVERY, Haematopoiesis, surgical procedures, operative, medicine.anatomical_structure, Settore MED/38 - PEDIATRIA GENERALE E SPECIALISTICA, Transplantation, Child, Preschool, 030220 oncology & carcinogenesis, HSCT, Female, Stem cell, Adult, medicine.medical_specialty, Adolescent, T cell, Human leukocyte antigen, Young Adult, 03 medical and health sciences, CD8-positive T-lymphocytes, haematopoietic stem cell transplantation, risk factors, Internal medicine, SCORE, medicine, Humans, IMMUNOTHERAPY, Aged, business.industry, ADULTS, BONE-MARROW-TRANSPLANTATION, Transplantation, Haploidentical, business, CD8, Stem Cell Transplantation, 030215 immunology, RESPONSES
Abstract

HLA-haploidentical haematopoietic stem cell transplantation (haplo-HSCT) is increasingly offered to patients with high-risk acute leukaemia. Unfortunately, haplo-HSCT is followed by a delayed immunoreconstitution. The aim of this EBMT registry study was to explore the clinical impact of lymphocyte subset counts after haplo-HSCT. We considered 144 leukaemic patients transplanted in the period 2001-2012. Pre-transplantation clinical variables and differential immune-cell counts (CD3, CD4, CD8 T cells, NK and B cells) measured before day 100 were evaluated for their capacity to predict overall survival, relapse mortality or non-relapse mortality (NRM). Negative prognostic factors for overall survival were advanced disease state at transplantation, host age and CMV seropositivity. Higher CD3, CD4 and CD8 counts were associated with a better overall survival and a lower NRM. Strikingly, when tested in multivariable analysis, higher CD3 and CD8 counts were still significantly associated with a lower NRM. These results indicate that an accelerated T-cell reconstitution correlates with less transplantation mortality, likely due to the protective role of T cells against viral infections. This observation suggests that CD8+ T-cell counts should be investigated as surrogate biomarkers of outcome in prospective haplo-HSCT trials.

Published
2019

26. External validation of models for KIR2DS1/KIR3DL1-informed selection of hematopoietic cell donors fails

Author

Schetelig, J., Baldauf, H., Heidenreich, F., Massalski, C., Frank, S., Sauter, J., Stelljes, M., Ayuk, F.A., Bethge, W.A., Bug, G., Klein, S., Wendler, S., Lange, V., Wreede, L.C. de, Furst, D., Kobbe, G., Ottinger, H.D., Beelen, D.W., Mytilineos, J., Fleischhauer, K., Schmidt, A.H., Bomhauser, M., German Cooperative Transp, and Deutsch Register Stammzelltransp

Subjects
Adult, Male, Oncology, medicine.medical_specialty, Genotype, Immunobiology and Immunotherapy, medicine.medical_treatment, Immunology, Medizin, Graft vs Host Disease, Human leukocyte antigen, Hematopoietic stem cell transplantation, Biochemistry, Donor Selection, Young Adult, Receptors, KIR, Internal medicine, medicine, Humans, Transplantation, Homologous, Cumulative incidence, Aged, Proportional Hazards Models, Retrospective Studies, Donor selection, Proportional hazards model, business.industry, Hazard ratio, Hematopoietic Stem Cell Transplantation, Receptors, KIR3DL1, Cell Biology, Hematology, Middle Aged, Transplantation, Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Female, Unrelated Donors, business, KIR3DL1
Abstract

Several studies suggest that harnessing natural killer (NK) cell reactivity mediated through killer cell immunoglobulin-like receptors (KIRs) could reduce the risk of relapse after allogeneic hematopoietic cell transplantation. Based on one promising model, information on KIR2DS1 and KIR3DL1 and their cognate ligands can be used to classify donors as KIR-advantageous or KIR-disadvantageous. This study was aimed at externally validating this model in unrelated donor hematopoietic cell transplantation. The impact of the predictor on overall survival (OS) and relapse incidence was tested in a Cox regression model adjusted for patient age, a modified disease risk index, Karnofsky performance status, donor age, HLA match, sex match, cytomegalovirus match, conditioning intensity, type of T-cell depletion, and graft type. Data from 2222 patients with acute myeloid leukemia or myelodysplastic syndrome were analyzed. KIR genes were typed by using high-resolution amplicon-based next-generation sequencing. In univariable analyses and subgroup analyses, OS and the cumulative incidence of relapse of patients with a KIR-advantageous donor were comparable to patients with a KIR-disadvantageous donor. The adjusted hazard ratio from the multivariable Cox regression model was 0.99 (Wald test, P = .93) for OS and 1.04 (Wald test, P = .78) for relapse incidence. We also tested the impact of activating donor KIR2DS1 and inhibition by KIR3DL1 separately but found no significant impact on OS and the risk of relapse. Thus, our study shows that the proposed model does not universally predict NK-mediated disease control. Deeper knowledge of NK-mediated alloreactivity is necessary to predict its contribution to graft-versus-leukemia reactions and to eventually use KIR genotype information for donor selection.

Published
2020

29. Common and well-documented HLA alleles: 2012 update to the CWD catalogue

Author

Mack, S. J., Cano, P., Hollenbach, J. A., He, J., Hurley, C. K., Middleton, D., Moraes, M. E., Pereira, S. E., Kempenich, J. H., Reed, E. F., Setterholm, M., Smith, A. G., Tilanus, M. G., Torres, M., Varney, M. D., Voorter, C. E. M., Fischer, G. F., Fleischhauer, K., Goodridge, D., Klitz, W., Little, A.-M., Maiers, M., Marsh, S. G. E., Müller, C. R., Noreen, H., Rozemuller, E. H., Sanchez-Mazas, A., Senitzer, D., Trachtenberg, E., and Fernandez-Vina, Marcelo

Published
2013
Full Text
View/download PDF

33. Genotypes and haplotypes in the 3′ untranslated region of the HLA-G gene and their association with clinical outcome of hematopoietic stem cell transplantation for beta-thalassemia

Author

Sizzano, F., Testi, M., Zito, L., Crocchiolo, R., Troiano, M., Mazzi, B., Turchiano, G., Torchio, M., Pultrone, C., Gregori, S., Chiesa, R., Gaziev, J., Sodani, P., Marktel, S., Amoroso, A., Roncarolo, M. G., Lucarelli, G., Ciceri, F., Andreani, M., and Fleischhauer, K.

Published
2012
Full Text
View/download PDF

38. Treosulfan-based conditioning regimen allows an early full donor chimerism after related and unrelated transplant with low toxicity. Results from a prospective single-centre study: P972

Author

Lorusso, A., Crotta, A., Messina, C., Ruggeri, A., Forno, B., Marcatti, M., Clerici, D., Lupo Stanghellini, M. T., Giglio, F., Mastaglio, S., Forcina, A., Malato, S., Lunghi, F., Assanelli, A., Gattillo, S., Ronchi, P., Fleischhauer, K., Bernardi, M., Corti, C., Ciceri, F., and Peccatori, J.

Published
2011

39. Non-permissive HLA-DPB1 T-cell epitope disparities are associated with non-relapse mortality after unrelated stem cell transplantation and are not dependent on HLA-DPA1: O406

Author

Fleischhauer, K., Spellman, S. R., Wang, T., Haagenson, M., Battiwalla, M., Baxter-Lowe, L. A., Dehn, J. W., Gajewski, J. L., Hale, G. A., Heemskerk, M. B., Lee, S. J., McCarthy, P., Miklos, D., Oudshoorn, M., Pollack, M. S., Marino, S., Reddy, V., Senitzer, D., Shaw, B., Waller, E. K., and Fernandez-Vina, M.

Published
2011

41. TK007 phase II study final analysis. Genetically modified donor lymphocytes abate transplant related mortality and increase leukaemia-free survival providing early immune reconstitution after haploidentical haematopoietic stem cell transplantation

Author

Lupo Stanghellini, M. T., Ciceri, F., Bonini, C., Bondanza, A., Traversari, C., Toma, S., Salomoni, M., Turchetto, L., Colombi, S., Bernardi, M., Peccatori, J., Pescarollo, A., Servida, P., Magnani, Z., Perna, S. K., Valtolina, V., Crippa, F., Callegaro, L., Spoldi, E., Fleischhauer, K., Ponzoni, M., Vago, L., Santoro, A., Todisco, E., Apperley, J., Slavin, S., Weissinger, E., Hertenstein, B., Bregni, M., Gallo Stampino, C., Bruzzi, P., and Bordignon, C.

Published
2008

50. Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders : current practice in Europe, 2019

Author

Duarte, R.F., Labopin, M., Bader, P., Basak, G.W., Bonini, C., Chabannon, C., Corbacioglu, S., Dreger, P., Dufour, C., Genneryl, A.R., Kuball, J., Lankester, A.C., Lanza, F., Montoto, S., Nagler, A., Latour, R.P. de, Snowden, J.A., Styczynski, J., Yakoub-Agha, I., Kroger, N., Mohty, M., Albert, M., Alexander, T., Averbuch, D., Baron, F., Bazarbachi, E., Beksac, M., Brissot, E., Bug, G., Cesaro, S., Chalandon, Y., Ciceri, F., Czerw, T., Dazzi, F., Esteve, J., Fleischhauer, K., Garderet, L., Giebel, S., Gil, L., Gilleece, M., Gorin, N.C., Hayden, P., Halter, J., Boluda, J.C.H., Hudecek, M., Kleinschmidt, K., Kenyon, M., Koenecke, C., Locatelli, F., Malard, F., McLornan, D., Mikulska, M., Murray, J., Onida, F., Pedrazzoli, P., Penack, O., Peric, Z., Risitano, A., Robin, M., Robinson, S., Ruggeri, A., Sanz, J., Savani, B., Schetelig, J., Schied, C., Schmid, C., Schoemans, H., Schonland, S., Sharrack, B., Shouval, R., Spyridonidis, A., Toubert, A., Tourniac, O., Urbano-Ispizua, A., Vago, L., Gelder, M. van, Verhoeven, B., Versluis, J., Wietten, L., Willasch, A., European Soc Blood Marrow Transpla, Duarte, R. F., Labopin, M., Bader, P., Basak, G. W., Bonini, C., Chabannon, C., Corbacioglu, S., Dreger, P., Dufour, C., Gennery, A. R., Kuball, J., Lankester, A. C., Lanza, F., Montoto, S., Nagler, A., Peffault de Latour, R., Snowden, J. A., Styczynski, J., Yakoub-Agha, I., Kroger, N., Mohty, M, and on behalf of the European Society forBlood and Marrow Transplantation, (EBMT)

Subjects
medicine.medical_specialty, Transplantation Conditioning, medicine.medical_treatment, MEDLINE, Disease, Hematopoietic stem cell transplantation, History, 21st Century, NO, 03 medical and health sciences, 0302 clinical medicine, Neoplasms, medicine, Humans, Intensive care medicine, Multiple myeloma, Accreditation, Transplantation, business.industry, Hematopoietic Stem Cell Transplantation, Hematology, medicine.disease, Hematologic Diseases, Europe, Immune System Diseases, Hematologic disease, 030220 oncology & carcinogenesis, business, 030215 immunology
Abstract

This is the seventh special EBMT report on the indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders. Our aim is to provide general guidance on transplant indications according to prevailing clinical practice in EBMT countries and centres. In order to inform patient decisions, these recommendations must be considered together with the risk of the disease, the risk of the transplant procedure and the results of non-transplant strategies. In over two decades since the first report, the EBMT indications manuscripts have incorporated changes in transplant practice coming from scientific and technical developments in the field. In this same period, the establishment of JACIE accreditation has promoted high quality and led to improved outcomes of patient and donor care and laboratory performance in transplantation and cellular therapy. An updated report with operating definitions, revised indications and an additional set of data with overall survival at 1 year and non-relapse mortality at day 100 after transplant in the commonest standard-of-care indications is presented. Additional efforts are currently underway to enable EBMT member centres to benchmark their risk-adapted outcomes as part of the Registry upgrade Project 2020 against national and/or international outcome data.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results